Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study.Pablo Tolosa, Eva Ciruelos, Tomás Pascual et al.|Journal of Clinical Oncology|2023Cited by 0
311P PFS2 and 3 after first-line CDK4/6i in HR+/HER2- metastatic breast cancer patients based on PAM50 intrinsic subtype and treatment strategies within the SOLTI-1801 CDK-PREDICT studyP. Tolosa Ortega, E.M. Ciruelos, Isabel García-Fructuoso et al.|ESMO Open|2025Cited by 0
248P Real-world relapse-free survival in HR+/HER2- breast cancer with PAM50 intermediate-risk groupSantiago Terán, Rodrigo Sánchez-Bayona, P. Tolosa Ortega et al.|ESMO Open|2025Cited by 0